Roche Cancer Drug Rises To Challenge Merck, Bristol-Myers

Tecentriq, a cancer immunotherapy developed by the Swiss drug giant Roche, slowed the progression of previously untreated lung cancer in a large clinical trial when combined with a chemotherapy regimen, the drug giant said.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: OTC:RHHBY NYSE:MRK NYSE:BMY NYSE:AZN Source Type: news